Dr. Vickie R. Shannon, MD

Dr. Shannon practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Shannon's NPI, 1013003151, was assigned on October 5, 2006. Dr. Shannon graduated from WashU Medicine in 1983. Dr. Shannon holds Texas license G7762.

Dr. Shannon's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Shannon's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shannon practices. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Shannon's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Shannon is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Shannon's licenses on file in 2 states: Texas and Florida.

Dmand AI lists asthma, chronic obstructive pulmonary disease (COPD), pleural effusion, pneumonia, pulmonary fibrosis and pulmonary heart disease among the conditions Dr. Shannon treats.

CMS data shows 971 Medicare services from Dr. Shannon across 13 procedure codes in 2024, for 425 Medicare patients. Medicare paid $38,152 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 425 Medicare patients who saw Dr. Shannon in 2024. The largest group is 65 to 74, with 225 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 3.10, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shannon's median patient age at 71, with 50% women.

In 2024, Dr. Shannon wrote 37 Medicare Part D claims for 22 patients. 49% of them were for generic drugs. CMS names the drug for 12 of them, across 1 drug with 11 or more claims each, at $300 in total drug cost. In 2016, CMS named 84 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Shannon for performance year 2024, reported as part of a group.

Dmand AI links 63 papers to Dr. Shannon, published from 2007 to 2025. 2020 was the busiest year, with 13. The most frequent topics are Immune Checkpoint Inhibitors, Lung Neoplasms and Pneumonia. Dr. Shannon has published most often in Am J Respir Crit Care Med. Dr. Shannon's most frequent co-authors are Saadia A. Faiz, MD, Ajay Sheshadri, MD and Lara Bashoura, MD.

Dmand AI links Dr. Shannon to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Lung Neoplasms and Thoracic Neoplasms.

CMS Open Payments shows 6 general payments to Dr. Shannon from 6 drug and device companies from 2016 to 2022. Consulting fees make up the largest share, 78% of the total. AstraZeneca Pharmaceuticals LP paid the most, $1,074.

Dr. Shannon graduated from WashU Medicine in 1983. Dr. Shannon is a member of ACP.

Dr. Shannon is in network with 17 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. HMO plans come from the most carriers, 10. Check the plan with the practice before a visit.